An In Silico Approach
Jose Luis Gonzalez-Llerena,Bryan Alejandro Espinosa-Rodriguez,Daniela Treviño-Almaguer,Luis Fernando Mendez-Lopez,Pilar Carranza-Rosales,Patricia Gonzalez-Barranco,Nancy Elena Guzman-Delgado,Antonio Romo-Mancillas,Isaias Balderas-Renteria
DOI: https://doi.org/10.3390/ijms25115692
IF: 5.6
2024-05-24
International Journal of Molecular Sciences
Abstract:Cordycepin, or 3′-deoxyadenosine, is an adenosine analog with a broad spectrum of biological activity. The key structural difference between cordycepin and adenosine lies in the absence of a hydroxyl group at the 3′ position of the ribose ring. Upon administration, cordycepin can undergo an enzymatic transformation in specific tissues, forming cordycepin triphosphate. In this study, we conducted a comprehensive analysis of the structural features of cordycepin and its derivatives, contrasting them with endogenous purine-based metabolites using chemoinformatics and bioinformatics tools in addition to molecular dynamics simulations. We tested the hypothesis that cordycepin triphosphate could bind to the active site of the adenylate cyclase enzyme. The outcomes of our molecular dynamics simulations revealed scores that are comparable to, and superior to, those of adenosine triphosphate (ATP), the endogenous ligand. This interaction could reduce the production of cyclic adenosine monophosphate (cAMP) by acting as a pseudo-ATP that lacks a hydroxyl group at the 3′ position, essential to carry out nucleotide cyclization. We discuss the implications in the context of the plasticity of cancer and other cells within the tumor microenvironment, such as cancer-associated fibroblast, endothelial, and immune cells. This interaction could awaken antitumor immunity by preventing phenotypic changes in the immune cells driven by sustained cAMP signaling. The last could be an unreported molecular mechanism that helps to explain more details about cordycepin's mechanism of action.
biochemistry & molecular biology,chemistry, multidisciplinary